海辰药业股价跌5.22%，华安基金旗下1只基金位居十大流通股东，持有89.03万股浮亏损失265.31万元

Core Viewpoint - On November 12, Haitian Pharmaceutical experienced a decline of 5.22%, with a stock price of 54.10 CNY per share, a trading volume of 187 million CNY, a turnover rate of 4.15%, and a total market capitalization of 6.492 billion CNY [1] Company Overview - Nanjing Haitian Pharmaceutical Co., Ltd. is located at No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone, Jiangsu Province, and was established on January 15, 2003, with its listing date on January 12, 2017 [1] - The company's main business involves the research, development, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Revenue Composition - The revenue composition of the company is as follows: - Cardiovascular drugs: 87.12% - Antibiotics: 5.69% - Active pharmaceutical ingredients and intermediates: 1.68% - Digestive drugs: 1.50% - Antiviral drugs: 1.47% - Others (supplements): 0.83% - Immune regulators: 0.80% - Other categories: 0.57% - Diuretics: 0.34% [1] Shareholder Information - Among the top ten circulating shareholders of Haitian Pharmaceutical, a fund under Huaan Fund ranks as a significant shareholder. The Huaan Medical Biotechnology Stock Initiation A (022690) entered the top ten circulating shareholders in the third quarter, holding 890,300 shares, which accounts for 1.08% of the circulating shares [2] - The Huaan Medical Biotechnology Stock Initiation A (022690) was established on December 25, 2024, with a latest scale of 694 million CNY. It has achieved a year-to-date return of 77.6%, ranking 54 out of 4216 in its category, and a cumulative return of 76.55% since inception [2] - The fund manager of Huaan Medical Biotechnology Stock Initiation A is Sang Xiangyu, who has been in the position for 2 years and 134 days, managing total fund assets of 6.379 billion CNY, with the best fund return during his tenure being 93.1% and the worst being 12.88% [2]